Article Information
History
- January 12, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Melchior Le Mene1,*,
- Vincent Allain2,*,
- Juliette Villemonteix1,
- Alexis Cuffel1,2,
- Jean-Luc Taupin1,2,
- Roberta di Blasi3,
- Catherine Thieblemont3 and
- Sophie Caillat-Zucman1,2,*
- 1Laboratoire d’Immunologie et Histocompatibilité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, 75010 Paris, France
- 2Institut national de la santé et de la recherche médicale (INSERM) UMR976, Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, 75010 Paris, France
- 5Service d’Hémato-oncologie, Hôpital Saint-Louis, AP-HP, Université Paris Cité, 75010 Paris, France
- ↵†Corresponding author :
Sophie Caillat-Zucman, Laboratoire d’Immunologie et Histocompatibilité, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France. Email : sophie.caillat-zucman{at}aphp.fr
↵* These authors contributed equally to this work.
Posted January 12, 2024.
Germline HLA-DQ genotype influences response to CAR T-cell therapy in patients with large B-cell lymphoma
